Table 1 Patient characteristics of therapy-related (t-MDS) and primary (p-MDS) myelodysplastic syndromes (additional information on patient characteristics regarding participating centers and year of diagnosis and a comparison of untreated patients only is shown in Supplementary Tables 1 and 2).

From: Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification—an approach to classification of patients with t-MDS

Characteristics	t-MDS patients (n = 1245)		p-MDS patients (n = 4593)		p
	n	%	n	%
MDS treatment
Treated^a	715	63%	0	0%
Untreated	422	37%	4593	100%
Total with information	1137	91%	4593	100%
Stem cell transplantation
Yes	210	19%	0	0%
No	906	81%	4593	100%
Total	1116	90%	4593
Age (years)					<0.001
≤60	342	28%	1053	23%
>60 to ≤70	395	32%	1267	27%
>70 to ≤80	404	32%	1601	35%
>80	104	8%	672	15%
Median	68		70
Total	1245	100%	4593	100%
Gender					<0.001
Male	680	55%	2854	62%
Female	565	45%	1739	38%
Total	1245	100%	4593	100%
FAB					<0.001
RA	490	40%	1707	37%
RARS	110	9%	839	18%
RAEB	455	38%	1217	27%
RAEB-T	81	7%	328	7%
CMML	44	4%	435	9%
Unclassified	29	2%	67	2%
Total	1209	97%	4593	100%
WHO					<0.001
RCUD	183	17%	639	17%
RARS	66	6%	507	13%
RCMD	335	31%	1097	29%
RAEB-1	246	22%	627	16%
RAEB-2	219	20%	748	19%
MDS (del5q)	13	1%	143	4%
MDS-U	29	3%	90	2%
Total	1091	88%	3851	84%
IPSS-R					<0.001
Very low	105	8%	893	19%
Low	260	21%	1644	36%
Intermediate	225	18%	882	19%
High	275	22%	628	14%
Very high	380	31%	546	12%
Total	1245	100%	4593	100%
WPSS-R					<0.001
Very low	83	8%	822	22%
Low	164	15%	1036	28%
Intermediate	228	21%	654	17%
High	399	38%	916	24%
Very high	188	18%	325	9%
Total	1062	85%	3753	82%
Cytogenetic risk categories (IPSS-R)-cipssr					<0.001
Very good	24	2%	150	3%
Good	460	37%	3261	71%
Intermediate	198	16%	622	14%
Poor	184	15%	197	4%
Very poor	379	30%	363	8%
Total	1245	100%	4593	100%
Number of cytogenetic aberrations					<0.001
0	377	30%	2753	73%
1	266	21%	706	19%
2	144	12%	136	4%
3	77	6%	55	2%
4	50	4%	28	1%
≥5	331	27%	76	2%
Total	1245	100%	3754	82%
Primary diagnosis
Hematological	529	43%
Breast	203	16%
Prostate	125	10%
Other solid tumor	342	28%
Non-malignant disease	43	3%
Total	1242	99,8%
Years from primary diagnosis to MDS
Median (years)	6.9
≤2	130	11%
>2 to ≤4	216	18%
>4 to ≤8	347	29%
>8 to ≤16	356	29%
>16	166	14%
Total	1215	98%
Therapy for primary disease
All chemotherapy	1000	80%
All radiation including radioiodine	676	54%
Radiation alone	243	19%
Radioactive iodine	11	1%
Chemotherapy alone	568	45%
Radiation and chemotherapy	431	35%
Total	1243	99,8%
Alkylating agents
Yes	536	65%
No	292	35%
Total	828	83%
Topoisomerase II inhibitors
Yes	356	43%
No	472	57%
Total	828	83%
Antitubulin agents
Yes	340	41%
No	488	59%
Total	828	83%
Antimetabolites
Yes	313	43%
No	515	57%
Total	828	83%

^aHMAs, chemotherapy, and/or allogeneic HSC transplant.

Back to article page

Table 1 Patient characteristics of therapy-related (t-MDS) and primary (p-MDS) myelodysplastic syndromes (additional information on patient characteristics regarding participating centers and year of diagnosis and a comparison of untreated patients only is shown in Supplementary Tables 1 and 2).

Search

Quick links